GlassScriptPhysician profile
Geeta Khare
NPI 1649377268
$10,629.33
in general payments reported to CMS, 2019-2025
29 companies · $4,290 in 2025
The $4,290 reported for 2025 was more than what 82% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $558 · 2021: $1,617 · 2022: $1,168 · 2023: $1,027 · 2024: $1,969 · 2025: $4,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,774 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,225 · Education: $197 · Travel and Lodging: $89.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,774.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,225.00 |
| Education | $197.05 |
| Travel and Lodging | $89.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,052.77 | 2020-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,092.84 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $832.26 | 2021-2025 | Dupixent |
| Genzyme Corporation | $806.21 | 2020-2025 | |
| Genentech USA, INC. | $544.26 | 2020-2025 | Xolair |
| Octapharma USA, INC. | $519.90 | 2020-2024 | Cutaquig |
| Takeda Pharmaceuticals U.S.A., INC. | $414.22 | 2020-2025 | Takhzyro, Hyqvia, Glassia |
| Pharming Healthcare, INC. | $300.61 | 2020-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $257.84 | 2024-2025 | |
| Kaleo, INC. | $255.50 | 2020-2023 | Auvi-Q |
| Pfizer INC. | $237.73 | 2020-2025 | |
| Csl Behring | $170.77 | 2022-2025 | Hizentra, Haegarda, Andembry |
| Biocryst US Sales Co., LLC | $165.54 | 2021-2025 | Orladeyo |
| Adma Biomanufacturing LLC | $150.00 | 2024 | |
| Grifols USA, LLC | $144.74 | 2021-2023 | Xembify |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $136.72 | 2021-2024 | |
| Amgen INC. | $107.42 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $76.99 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $54.88 | 2021 | |
| Incyte Corporation | $53.56 | 2024-2025 | Opzelura |
| Merck Sharp & Dohme LLC | $49.86 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.09 | 2020-2021 | |
| Galderma Laboratories, L.P. | $35.74 | 2025 | Nemluvio |
| Tersera Therapeutics LLC | $28.57 | 2022 | |
| Horizon Therapeutics Plc | $27.88 | 2022 | |
| Abbvie INC. | $23.66 | 2022 | |
| Cycle Pharmaceuticals INC | $17.48 | 2025 | Sajazir |
| Greer Laboratories, INC. | $15.23 | 2024 | Oralair |
| Ars Pharmaceuticals Operations, INC. | $14.06 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geeta Khare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.